Durvalumab is an immune checkpoint inhibitor (ICI) that selectively binds to Programmed cell-death 1 ligand 1 (PD-L1) and inhibits its interactions with Programmed cell death-1 (PD-1) and CD80 resulting in T cell activation and anti-tumor responses (1). The gene discussed is CD274; the disease is neoplasm.